Inhibitory Effect of Bovine Lactoferrin on Human Parainfluenza Virus Type 2 Infection

Yamamoto, Hidetaka; Ura, Yukari; Tanemura, Miho; Koyama, Aoi; Takano, Sayaka; Uematsu, Jun; Kawano, Mitsuo; Tsurudome, Masato; O’Brien, Myles; Komada, Hiroshi

doi:10.1248/jhs.56.613

Cited by 12 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Successively, Sanoand co-workers [ 109 ] showed that RSV-induced IL-8 secretion from HEp-2 cells was down regulated by lactoferrin and that both RSV infectivity and uptake were decreased by lactoferrin treatment. Toclarify the mechanism of this effect, the interaction of lactoferrin with RSV F protein, the mostimportant surface glycoprotein for viral penetration, was examined and results obtained showed thatlactoferrin directly interacted with the F (1) subunit, which involved antigenic sites of F protein [ 109 ].Concerning PIV, Lf exhibits antiviral activity against hPIV-2 by inhibiting virus adsorption to the surface of the cells thus preventing viral infection and replication [ 110 ].…”

Section: Inhibition Of Viral Infections By Lactoferrinmentioning

confidence: 99%

Antiviral Properties of Lactoferrin—A Natural Immunity Molecule

et al. 2011

View full text Add to dashboard Cite

Lactoferrin, a multifunctional iron binding glycoprotein, plays an important role in immune regulation and defence mechanisms against bacteria, fungi and viruses. Lactoferrin’s iron withholding ability is related to inhibition of microbial growth as well as to modulation of motility, aggregation and biofilm formation of pathogenic bacteria. Independently of iron binding capability, lactoferrin interacts with microbial, viral and cell surfaces thus inhibiting microbial and viral adhesion and entry into host cells. Lactoferrin can be considered not only a primary defense factor against mucosal infections, but also a polyvalent regulator which interacts in viral infectious processes. Its antiviral activity, demonstrated against both enveloped and naked viruses, lies in the early phase of infection, thus preventing entry of virus in the host cell. This activity is exerted by binding to heparan sulphate glycosaminoglycan cell receptors, or viral particles or both. Despite the antiviral effect of lactoferrin, widely demonstrated in vitro studies, few clinical trials have been carried out and the related mechanism of action is still under debate. The nuclear localization of lactoferrin in different epithelial human cells suggests that lactoferrin exerts its antiviral effect not only in the early phase of surface interaction virus-cell, but also intracellularly. The capability of lactoferrin to exert a potent antiviral activity, through its binding to host cells and/or viral particles, and its nuclear localization strengthens the idea that lactoferrin is an important brick in the mucosal wall, effective against viral attacks and it could be usefully applied as novel strategy for treatment of viral infections.

show abstract

Section: Inhibition Of Viral Infections By Lactoferrinmentioning

confidence: 99%

Antiviral Properties of Lactoferrin—A Natural Immunity Molecule

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Here, we report that ASL from the airways of pigs and humans exhibits Several mechanisms are responsible for the antiviral actions of these proteins and peptides, including direct binding to and aggregation of viruses through interactions with lipid bilayers and/or viral glycoproteins, and in some cases disruption of viral membranes (40,41). In contrast, lactoferrin inhibits parainfluenza virus 2 (PIV2) infection by binding to cellular proteins rather than through direct interaction with the virus (43). Additionally, airway mucins are thought to contribute to antiviral defenses by interacting with viruses in ways that impede their movement and/or prevent their uptake (48)(49)(50).…”

Section: Discussionmentioning

confidence: 99%

Airway Surface Liquid Has Innate Antiviral Activity That Is Reduced in Cystic Fibrosis

Berkebile¹,

Bartlett²,

Alaiwa³

et al. 2020

Am J Respir Cell Mol Biol

View full text Add to dashboard Cite

While chronic bacterial infections and inflammation are associated with progressive lung disease in cystic fibrosis (CF) patients, much less is known regarding the contributions of respiratory viral infections to this process. Clinical studies suggest that antiviral host defenses may be compromised in individuals with CF, and CF airway epithelia exhibit impaired antiviral responses in vitro. Here, we used the CF pig model to test the hypothesis that the antiviral activity of respiratory secretions is reduced in CF. We developed an in vitro assay to measure the innate antiviral activity present in airway surface liquid (ASL) from CF and non-CF pigs. We found that tracheal and nasal ASL from newborn non-CF pigs exhibited dose-dependent inhibitory activity against several enveloped and encapsidated viruses including Sendai virus (SeV), respiratory syncytial virus (RSV), influenza A, and adenovirus. Importantly, we found that the anti-SeV activity of nasal ASL from newborn CF pigs was significantly diminished relative to non-CF littermate controls. This diminution of extracellular antiviral defenses appears to be driven, at least in part, by the differences in pH between CF and non-CF ASL. These data highlight the novel antiviral properties of native airway secretions, and suggest the possibility that defects in extracellular antiviral defenses contribute to CF pathogenesis.

show abstract

“…In Madin-Darby canine kidney cells, human LF (20-80 µg/mL) demonstrated enhanced antiviral activity against avian IAV in a dose-dependent manner [85]. In addition, bovine LF inhibited parainfluenza virus replication in vitro and decreased viral adsorption onto cells, thereby preventing viral entry [86]. Together these results highlight the possible role of LF in preventing influenza and parainfluenza virus infections.…”

Section: Transferrinsmentioning

confidence: 99%

Human Antimicrobial Peptides as Therapeutics for Viral Infections

Ahmed

Siman-Tov

Hall

et al. 2019

Viruses

182

181

View full text Add to dashboard Cite

Successful in vivo infection following pathogen entry requires the evasion and subversion of multiple immunological barriers. Antimicrobial peptides (AMPs) are one of the first immune pathways upregulated during infection by multiple pathogens, in multiple organs in vivo. In humans, there are many classes of AMPs exhibiting broad antimicrobial activities, with defensins and the human cathelicidin LL-37 being the best studied examples. Whereas historically the efficacy and therapeutic potential of AMPs against bacterial infection has been the primary focus of research, recent studies have begun to elucidate the antiviral properties of AMPs as well as their role in regulation of inflammation and chemoattraction. AMPs as therapeutic tools seem especially promising against emerging infectious viral pathogens for which no approved vaccines or treatments are currently available, such as dengue virus (DENV) and Zika virus (ZIKV). In this review, we summarize recent studies elucidating the efficacy and diverse mechanisms of action of various classes of AMPs against multiple viral pathogens, as well as the potential use of human AMPs in novel antiviral therapeutic strategies.

show abstract

Inhibitory Effect of Bovine Lactoferrin on Human Parainfluenza Virus Type 2 Infection

Cited by 12 publications

References 23 publications

Antiviral Properties of Lactoferrin—A Natural Immunity Molecule

Antiviral Properties of Lactoferrin—A Natural Immunity Molecule

Airway Surface Liquid Has Innate Antiviral Activity That Is Reduced in Cystic Fibrosis

Human Antimicrobial Peptides as Therapeutics for Viral Infections

Contact Info

Product

Resources

About